trending Market Intelligence /marketintelligence/en/news-insights/trending/VGYuqEGyMLzCVbZZhIVwFw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Jazz Pharmaceuticals' Sunosi gets US FDA approval to treat sleep disorder

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Jazz Pharmaceuticals' Sunosi gets US FDA approval to treat sleep disorder

Jazz Pharmaceuticals plc said the U.S. Food and Drug Administration approved Sunosi as a treatment for a type of sleep disorder.

Sunosi, or or solriamfetol, is now approved to treat excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

Narcolepsy is a neurological disorder affecting control of sleep and wakefulness. It is characterized by excessive sleepiness and inability to regulate sleep-wake cycles normally. Obstructive sleep apnea is a disorder that causes breathing to repeatedly stop and start during sleep with excessive sleepiness as one of its major symptoms.

The FDA approval is based on data from a phase 3 clinical program called Tones, which included four studies showing Sunosi was better than placebo at treating the disease.

The drug is expected to be available in the U.S. after the U.S. Drug Enforcement Administration makes a final scheduling decision, usually within 90 days of FDA approval.

Dublin-based Jazz has also submitted an application to the European Medicines Agency seeking approval for solriamfetol in the same indications.

The Irish drugmaker, whose top-selling drug Xyrem also treats narcolepsy as well as cataplexy, acquired rights to develop and commercialize solriamfetol from Aerial BioPharma LLC in 2014.